INDICATIONS AND USAGE
CADUET (amlodipine and atorvastatin) is indicated in patients for
whom treatment with both amlodipine and atorvastatin is appropriate.
Amlodipine1.
Hypertension
:
Amlodipine is indicated for the treatment of hypertension. It may be used alone
or in combination with other antihypertensive agents;
2.
Coronary Artery Disease (CAD)
Chronic Stable Angina: Amlodipine is indicated for the
treatment of chronic stable angina. Amlodipine may be used alone or in
combination with other antianginal or antihypertensive agents;
Vasospastic Angina (Prinzmetal's or Variant Angina):
Amlodipine is indicated for the treatment of confirmed or suspected vasospastic
angina. Amlodipine may be used as monotherapy or in combination with other
antianginal drugs.
Angiographically Documented
CAD: In patients with recently documented CAD by angiography and without
heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce
the risk of hospitalization due to angina and to reduce the risk of a coronary
revascularization procedure. AND
AtorvastatinTherapy with lipid-altering agents should be only one component
of multiple risk factor intervention in individuals at significantly increased
risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug
therapy is recommended as an adjunct to diet when the response to a diet
restricted in saturated fat and cholesterol and other nonpharmacologic measures
alone has been inadequate. In patients with CHD or multiple risk factors for
CHD, the atorvastatin component of CADUET can be started simultaneously with
diet restriction.1.
Prevention of Cardiovascular Disease: In
adult patients without clinically evident coronary heart disease, but with
multiple risk factors for coronary heart disease such as age, smoking,
hypertension, low HDL-C, or a family history of early coronary heart disease,
atorvastatin is indicated to:
Reduce the risk of myocardial infarction
Reduce the risk of stroke
Reduce the risk for revascularization procedures and angina
In
patients with type 2 diabetes, and without clinically evident coronary heart
disease, but with multiple risk factors for coronary heart disease such as
retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to:
Reduce the risk of myocardial infarction
Reduce the risk of stroke;
In patients with clinically evident
coronary heart disease, LIPITOR is indicated to:
Reduce the risk of non-fatal myocardial infarction
Reduce the risk of fatal and non-fatal stroke
Reduce the risk for revascularization procedures
Reduce the risk of hospitalization for CHF
Reduce the risk of angina
2.
Heterozygous Familial and Nonfamilial
Hyperlipidemia
: Atorvastatin is indicated as an
adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to
increase HDL-C in patients with primary hypercholesterolemia (heterozygous
familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb);
3.
Elevated Serum TG Levels
: Atorvastatin is indicated as an adjunct to diet for the
treatment of patients with elevated serum TG levels (Fredrickson Type IV);
4.
Primary Dysbetalipoproteinemia
: Atorvastatin is indicated for the treatment of patients with
primary dysbetalipoproteinemia (Fredrickson Type III)
who do not respond adequately to diet;
5.
Homozygous Familial Hypercholesterolemia
: Atorvastatin is indicated to reduce total-C and LDL-C in
patients with homozygous familial hypercholesterolemia as an adjunct to other
lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are
unavailable;
6.
Pediatric Patients
:
Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and
apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with
heterozygous familial hypercholesterolemia if after an adequate trial of diet
therapy the following findings are present:
LDL-C remains greater than or equal to 190 mg/dL or
LDL-C remains greater than or equal to 160 mg/dL and:
there is a positive family history of premature cardiovascular disease or
two or more other CVD risk factors are present in the pediatric patients.
The antidyslipidemic component of CADUET has not been studied in conditions
where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).